You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
會議邀請|東曜藥業ADC藥物TAA013臨牀I期結果投資者線上分享會
格隆匯 12-03 10:14

尊敬的分析師及投資者:

東曜藥業自主研發的抗體偶聯藥物(ADC)TAA013的臨牀I期研究數據將在近期第43屆聖安東尼奧乳腺癌大會(SABCS)發表。作為東曜藥業核心產品之一,TAA013目前處於臨牀III期患者招募階段,並已於2020年7月完成首例受試者入組。此次將主要針對臨牀I期研究結果召開線上分享會,更好的為大家解讀臨牀結果。

TAA013是一種含有曲妥珠單抗和美坦新衍生物(曲妥珠-MCC-DM1)的在研ADC藥物,旨在為HER2陽性乳腺癌患者提供兼具高質量與可負擔的治療選擇。TAA013作為東曜藥業核心產品之一,目前處於臨牀III期患者招募階段,已於7月完成首例受試者入組。

會議時間:2020年12月11日(週五) 上午 10:00-10:50

會議形式:騰訊網絡會議/格隆匯網站及APP同步直播

出席嘉賓:

▷劉軍博士 首席執行官和首席科學官

▷劉敏醫師 首席醫學官和副總經理

主講嘉賓:劉敏醫師

劉敏 首席醫學官和副總經理

▷劉敏醫師介紹:

· 主要負責東曜藥業多個產品的臨牀試驗策略規劃、設計及執行,主導完成TAB008生物類似藥臨牀I期和III期試驗、TAA013臨牀I期試驗,且負責的TAB014關鍵臨牀試驗也即將啟動

· 具有30多年腫瘤臨牀治療經驗,並擁有14年藥物及腫瘤標誌物方面的經驗

· 在SCI等國內外期刊發表80多篇腫瘤領域論文

報名方式:

方式1:掃描上方海報二維碼或者點擊下方鏈接報名:

https://bizadmin.gelonghui.com/manage

方式2:掃描二維碼添加格隆匯機構客服微信直接報名,報名需發送名片或者個人職業工作等信息供審核:

會議説明: 

本場會議邀請感興趣的投資機構、分析師、相關領域產業人士/專家以及其他感興趣的投資者朋友參會

。參會信息在您提交報名信息之後我們會通過短信和郵件的方式通知您,請您確保信息填寫準確,如有任何疑問歡迎諮詢格隆匯機構客服微信(glh-jg)/郵箱(jg@gelonghui.com)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account